{
    "root": "7a3986a4-e684-4dd9-8dee-ae95af352efc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Divalproex Sodium",
    "value": "20250508",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "ETHYL ACRYLATE",
            "code": "71E6178C9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_82327"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)",
            "code": "74G4R6TH13",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "divalproex sodium extended-release tablets indicated : \u2022 acute treatment manic mixed episodes associated bipolar disorder , without psychotic features ( 1.1 ) . \u2022 monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1.2 ) . \u2022 prophylaxis migraine headaches ( 1.3 ) .",
        "doid_entities": [
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "divalproex sodium extended-release tablets extended-release product intended once-a-day oral . divalproex sodium extended-release tablets swallowed whole crushed chewed .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "divalproex sodium extended-release tablets usp , 250 mg available white off-white , round , coated tablets imprinting \u201c 755 \u201d one side plain side . divalproex sodium extended-release tablet , usp contains divalproex sodium , usp equivalent 250 mg valproic acid . cartons 80 extended-release tablets ( 10 extended-release tablets blister pack x 8 ) , ndc 0904-7181-45 cartons 100 extended-release tablets ( 10 extended-release tablets blister pack x 10 ) , ndc 0904-7181-61 divalproex sodium extended-release tablets usp , 500 mg available white off-white , capsule shaped , coated tablets imprinting \u201c 757 \u201d one side plain side . divalproex sodium extended-release tablet , usp contains divalproex sodium , usp equivalent 500 mg valproic acid . cartons 80 extended-release tablets ( 10 extended-release tablets blister pack x 8 ) , ndc 0904-7182-45 cartons 100 extended-release tablets ( 10 extended-release tablets blister pack x 10 ) , ndc 0904-7182-61 recommended storage : store tablets 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022divalproex sodium extended-release tablets administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . \u2022divalproex sodium extended-release tablets contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . \u2022divalproex sodium extended-release tablets contraindicated patients known hypersensitivity [ ( 5.12 ) ] . \u2022divalproex sodium extended-release tablets contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . \u2022for prophylaxis migraine headaches : divalproex sodium extended-release tablets contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "indications_original": "Divalproex sodium extended-release tablets are indicated for: \u2022 Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features (1.1). \u2022 Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1.2). \u2022 Prophylaxis of migraine headaches (1.3) .",
    "contraindications_original": "Divalproex sodium extended-release tablets are an extended-release product intended for once-a-day oral administration. Divalproex sodium extended-release tablets should be swallowed whole and should not be crushed or chewed.",
    "warningsAndPrecautions_original": "Divalproex sodium extended-release tablets USP, 250 mg are available as white to off-white, round, coated tablets with imprinting \u201cAN 755\u201d on one side and plain on the other side. Each divalproex sodium extended-release tablet, USP contains divalproex sodium, USP equivalent to 250 mg of valproic acid. \n                  Cartons of 80 extended-release tablets (10 extended-release tablets each blister pack x 8), NDC 0904-7181-45 \n                  Cartons of 100 extended-release tablets (10 extended-release tablets each blister pack x 10), NDC 0904-7181-61\n                  Divalproex sodium extended-release tablets USP, 500 mg are available as white to off-white, capsule shaped, coated tablets with imprinting \u201cAN 757\u201d on one side and plain on the other side. Each divalproex sodium extended-release tablet, USP contains divalproex sodium, USP equivalent to 500 mg of valproic acid.\n                  Cartons of 80 extended-release tablets (10 extended-release tablets each blister pack x 8), NDC 0904-7182-45\n                  Cartons of 100 extended-release tablets (10 extended-release tablets each blister pack x 10), NDC 0904-7182-61\n                  Recommended Storage: \n                  Store tablets at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022Divalproex sodium extended-release tablets should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)]. \n                     \n                        \u2022Divalproex sodium extended-release tablets are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)]. \n                     \n                        \u2022Divalproex sodium extended-release tablets are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)]. \n                     \n                        \u2022Divalproex sodium extended-release tablets are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)]. \n                     \n                        \u2022For use in prophylaxis of migraine headaches: Divalproex sodium extended-release tablets are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2,\u00a05.3,\u00a05.4)\u00a0and\u00a0\n                           Use in Specific Populations (8.1)].",
    "drug": [
        {
            "name": "Divalproex Sodium"
        }
    ]
}